James Hohmann @jameshohmann
The FDA’s situation is further complicated by an inexperienced commissioner who former agency leaders say failed at a critical task: to clearly explain the complicated “risk-benefit” calculation that goes into every drug authorization or approval. https://t.co/E8G9NkDnRg — PolitiTweet.org